You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The RNAi-based drug is designed to specifically target the strain of the virus responsible for the current outbreak.
The money from the Massachusetts Life Sciences Center will go toward developing a test that does not require laboratory instrumentation.
The award will go to David Alland to create an Ebola test using the same technology as a TB assay marketed by Cepheid.
The portable analyzer runs an RT-qPCR-based Ebola assay and takes about 75 minutes to detect the presence of the virus from whole blood.
BioInnovation Solutions, formerly Pathogenica, and Enzymatics are developing a rapid Ebola diagnostic and have validated it on patient samples in Nigeria.
The tests use the company's Nanotrap reagents, hydrogel nanoparticles functionalized with internal affinity baits to enrich target analytes for downstream analysis.
Qiagen announced today it will offer global distribution of the Altona Diagnostics RealStar Ebolavirus RT-PCR Kit 1.0.
The firms intend to seek Emergency Use Authorization from the US Food and Drug Administration once the Ebola assay is developed.
Point-of-care testing, automation, and panelization of nucleic acid amplification testing are the future of the clinical lab ― and will likely change how labs and clinicians relate.
The method may be deployed as part of the Broad's collaboration with Illumina and USAID to study Ebola in some West African countries hit by the outbreak.
The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.
Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.
A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.
In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.